• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[舒张性心力衰竭:治疗方式]

[Diastolic cardiac failure: therapeutic modalities].

作者信息

Millaire A

机构信息

Service de cardiologie C, hôpital Cardiologique, CHRU de Lille.

出版信息

Arch Mal Coeur Vaiss. 1998 Nov;91(11):1365-9.

PMID:9864605
Abstract

The management of cardiac failure due to diastolic dysfunction is not well codified and is often empirical. It has three objectives: improving the physiopathological components of ventricular filling, treating the associated aggravating pathological conditions, and treating the basic cause of the dysfunction. Symptomatic treatment aims to reduce venous congestion (by diuretics or nitrate derivatives), to prolong the diastolic period by slowing the heart rate (by betablockers, bradycardising calcium antagonists or digitalis in cases of irreducible atrial fibrillation), to improve passive ventricular distensibility by an effect on remodelling (by angiotensin converting enzyme inhibitors or anti-aldosterone diuretics). The treatment of associated pathological conditions is particularly important. It is essential to maintain or reestablish an effective atrial systole by cardioversion and anti-arrhythmic drugs in atrial fibrillation, by dual chamber pacing in cases of atrioventricular asynchrony due to atrioventricular block. Treatment of the underlying cause aims to induce regression of ventricular hypertrophy of hypertensive origin by using antihypertensive drugs with this property. In coronary artery disease, the choice is determined by the clinical context because nearly all anti-anginal or interventional treatments may improve ischaemic diastolic dysfunction. The same applies in hypertrophic cardiomyopathy because most types of treatment (betablockers, verapamil, cardiac pacing, surgery) may improve diastolic function. Finally, in valvular aortic stenosis, aortic valve replacement restores normal diastolic function.

摘要

舒张功能障碍所致心力衰竭的管理尚未形成完善的规范,往往基于经验。其有三个目标:改善心室充盈的病理生理成分,治疗相关的加重病理状况,以及治疗功能障碍的根本原因。对症治疗旨在减轻静脉淤血(通过利尿剂或硝酸酯类药物),通过减慢心率延长舒张期(通过β受体阻滞剂、减慢心率的钙拮抗剂或在房颤无法控制时使用洋地黄),通过对重塑的作用改善心室被动扩张能力(通过血管紧张素转换酶抑制剂或抗醛固酮利尿剂)。治疗相关病理状况尤为重要。在房颤时,通过心脏复律和抗心律失常药物维持或重建有效的心房收缩至关重要,在因房室传导阻滞导致房室不同步的情况下,通过双腔起搏来实现。治疗根本原因旨在通过使用具有此特性的抗高血压药物使高血压所致的心室肥厚消退。在冠状动脉疾病中,选择取决于临床情况,因为几乎所有抗心绞痛或介入治疗都可能改善缺血性舒张功能障碍。肥厚型心肌病也是如此,因为大多数类型的治疗(β受体阻滞剂、维拉帕米、心脏起搏、手术)都可能改善舒张功能。最后,在主动脉瓣狭窄时,主动脉瓣置换可恢复正常舒张功能。

相似文献

1
[Diastolic cardiac failure: therapeutic modalities].[舒张性心力衰竭:治疗方式]
Arch Mal Coeur Vaiss. 1998 Nov;91(11):1365-9.
2
[Heart failure due to diastolic dysfunction: the treatment principles].[舒张功能障碍所致心力衰竭:治疗原则]
Ital Heart J Suppl. 2000 Apr;1(4):469-80.
3
[Left ventricular insufficiency: systolic versus diastolic dysfunction].左心室功能不全:收缩期与舒张期功能障碍
Schweiz Med Wochenschr. 1994 Jul 2;124(26):1196-202.
4
Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure.高血压性心脏病的机制与管理:从左心室肥厚到心力衰竭
Med Clin North Am. 2004 Sep;88(5):1257-71. doi: 10.1016/j.mcna.2004.06.002.
5
Management of diastolic heart failure--a practical review of pathophysiology and treatment trial data.舒张性心力衰竭的管理——病理生理学与治疗试验数据的实用综述
Int J Clin Pract. 2005 Oct;59(10):1239-46. doi: 10.1111/j.1368-5031.2005.00642.x.
6
Diastolic dysfunction in congestive heart failure.充血性心力衰竭中的舒张功能障碍
Clin Pharm. 1991 Nov;10(11):850-61.
7
Therapy for diastolic heart failure.舒张性心力衰竭的治疗
Prog Cardiovasc Dis. 2005 May-Jun;47(6):380-8. doi: 10.1016/j.pcad.2005.02.004.
8
Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.老年人左心室收缩功能正常的左心室舒张性心力衰竭
J Lab Clin Med. 2001 May;137(5):316-23. doi: 10.1067/mlc.2001.114106.
9
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.双腔与VVI植入式心脏除颤器(DAVID)试验:原理、设计、结果、临床意义及对未来试验的启示
Card Electrophysiol Rev. 2003 Dec;7(4):468-72. doi: 10.1023/B:CEPR.0000023165.20987.b1.
10
Hypertension and heart failure: a dysfunction of systole, diastole or both?高血压与心力衰竭:是收缩功能障碍、舒张功能障碍还是两者皆有?
J Hum Hypertens. 2009 May;23(5):295-306. doi: 10.1038/jhh.2008.141. Epub 2008 Nov 27.

引用本文的文献

1
Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.药物难治性或药物不耐受性肥厚型心肌病的起搏治疗
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008523. doi: 10.1002/14651858.CD008523.pub2.